Metabolomics is defined as the identification and quantification of metabolic products in a biological system. As part of this Spotlight, we explore the recent advances in target and untargeted metabolomics and review the use of metabolomics in drug development and precision medicine.
Browsing: drug development
Brendan Griffin (University College Cork, Ireland) discusses his work in early drug development in this interview with Bioanalysis Zone. Brendan talks about the most common challenges faced as well as key trends in the field of developability.
Medicines Discovery Catapult (Cheshire, UK), Retrogenix (High Peak, UK) and Peak Proteins (Cheshire, UK) have entered a new three-way collaboration to identify potential target receptors for COVID-19 therapies.
In this interview we caught up with Hua Li (Boehringer Ingelheim Pharmaceuticals, CT, USA) to discuss her research and the inspiration for her 2018 Bioanalysis publication concerning the use of Mitra® microsampling for PK bioanalysis of monoclonal antibodies.
Our society is rightly concerned about the impact of COVID-19 and its economic repercussions but imagine the cost in human lives if 6 months or more of drug development shuts down.
Biomarkers are used to improve diagnosis and monitor a therapeutic response. During biomarker discovery ideal candidates are identified.
LGC (Cambridge, UK) have become the first bioanalytical CRO in Europe to offer the Quanterix Simoa HD-X automated analyzer in a regulated environment.
In this editorial Helen Shen (QPS; PA, USA) discusses the projected growth in the global small molecule discovery market and what impact this may have on the management of chronic diseases as well as what to look for when partnering with a CRO for small molecule studies.
Researchers have discovered unique populations of neurons in the spinal cords of patients who died of amyotrophic lateral sclerosis that could be utilized as potential drug targets.
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis
In this White Paper from Bioanalysis the authors highlight the need the bioanalytical community has for commercial kits able to be used for regulated drug development.